Cargando…

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

This survey study assesses the occurrence of short-term adverse events in adults 60 years or older who received a booster dose of the BNT162B2 mRNA vaccine.

Detalles Bibliográficos
Autores principales:	Auster, Oren, Finkel, Uriah, Dagan, Noa, Barda, Noam, Laufer, Alon, Balicer, Ran D., Ben-Shachar, Shay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016488/ https://www.ncbi.nlm.nih.gov/pubmed/35435973 http://dx.doi.org/10.1001/jamanetworkopen.2022.7657

Ejemplares similares

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
por: Kustin, Talia, et al.
Publicado: (2021)

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population
por: Ben Shachar, Shay, et al.
Publicado: (2021)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
por: Witberg, Guy, et al.
Publicado: (2021)

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
por: Dagan, Noa, et al.
Publicado: (2022)

Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Developing a COVID-19 mortality risk prediction model when individual-level data are not available
por: Barda, Noam, et al.
Publicado: (2020)

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
por: Hayek, Samah, et al.
Publicado: (2022)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers
por: Lee, Dong Yeop, et al.
Publicado: (2023)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
por: Katz, Mark A., et al.
Publicado: (2022)

Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients—A Prospective Cohort Study
por: Shostak, Yael, et al.
Publicado: (2023)

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
por: Sasajima, Hirofumi, et al.
Publicado: (2022)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
por: Waxman, Jacob G., et al.
Publicado: (2022)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
por: Athanasiou, Nikolaos K., et al.
Publicado: (2023)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
por: Martora, Fabrizio, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
por: Yanay, Noa Berar, et al.
Publicado: (2021)

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
por: Rosman, Yossi, et al.
Publicado: (2021)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds
por: Ribak, Yaarit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ot3f6fcduu7ld5rbnvrv644lr5